Jim Simons United Therapeutics Corp Transaction History

Renaissance Technologies LLC

$62.3 Billion
Q1 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in United Therapeutics Corp stock. As of the latest transaction made, Renaissance Technologies LLC holds 2,106,992 shares of UTHR stock, worth $672 Million. This represents 1.04% of its overall portfolio holdings.

Number of Shares

2,106,992

Previous 2,089,392 0.84%

Holding current value

$672 Million

Previous $737 Million 11.9%

% of portfolio

1.04%

Previous 1.16%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$304.42 - $380.78 $5.36 Million - $6.7 Million	17,600 Added 0.84%	2,106,992 $650 Million
Q4 2024 Feb 13, 2025	SELL	$348.66 - $410.0 $23 Million - $27.1 Million	-66,000 Reduced 3.06%	2,089,392 $737 Million
Q3 2024 Nov 13, 2024	SELL	$311.04 - $363.55 $6 Million - $7.02 Million	-19,300 Reduced 0.89%	2,155,392 $772 Million
Q2 2024 Aug 09, 2024	BUY	$228.26 - $319.04 $5.24 Million - $7.33 Million	22,978 Added 1.07%	2,174,692 $693 Million
Q1 2024 May 13, 2024	SELL	$210.76 - $249.51 $3.9 Million - $4.62 Million	-18,500 Reduced 0.85%	2,151,714 $494 Million
Q4 2023 Feb 13, 2024	SELL	$214.88 - $256.94 $17.3 Million - $20.6 Million	-80,294 Reduced 3.57%	2,170,214 $477 Million
Q3 2023 Nov 14, 2023	BUY	$211.82 - $248.24 $13.4 Million - $15.7 Million	63,294 Added 2.89%	2,250,508 $508 Million
Q2 2023 Aug 11, 2023	SELL	$205.19 - $232.99 $8.25 Million - $9.37 Million	-40,200 Reduced 1.8%	2,187,214 $483 Million
Q1 2023 May 12, 2023	SELL	$212.99 - $276.17 $24.9 Million - $32.3 Million	-117,078 Reduced 4.99%	2,227,414 $499 Million
Q4 2022 Feb 13, 2023	SELL	$205.95 - $280.43 $42.4 Million - $57.7 Million	-205,722 Reduced 8.07%	2,344,492 $652 Million
Q3 2022 Nov 14, 2022	SELL	$203.3 - $244.17 $49.5 Million - $59.4 Million	-243,377 Reduced 8.71%	2,550,214 $534 Million
Q2 2022 Aug 12, 2022	BUY	$174.81 - $241.14 $4.96 Million - $6.84 Million	28,378 Added 1.03%	2,793,591 $658 Million
Q1 2022 May 13, 2022	SELL	$166.16 - $213.96 $25.3 Million - $32.5 Million	-151,978 Reduced 5.21%	2,765,213 $496 Million
Q4 2021 Feb 11, 2022	SELL	$184.32 - $216.08 $20.5 Million - $24.1 Million	-111,400 Reduced 3.68%	2,917,191 $630 Million
Q3 2021 Nov 12, 2021	SELL	$179.86 - $214.88 $14.7 Million - $17.5 Million	-81,600 Reduced 2.62%	3,028,591 $559 Million
Q2 2021 Aug 13, 2021	SELL	$170.47 - $211.93 $16.6 Million - $20.6 Million	-97,400 Reduced 3.04%	3,110,191 $558 Million
Q1 2021 May 13, 2021	SELL	$153.94 - $174.85 $61.5 Million - $69.9 Million	-399,700 Reduced 11.08%	3,207,591 $537 Million
Q4 2020 Feb 10, 2021	SELL	$101.87 - $151.79 $10.4 Million - $15.4 Million	-101,727 Reduced 2.74%	3,607,291 $548 Million
Q3 2020 Nov 13, 2020	SELL	$99.9 - $121.13 $1.78 Million - $2.16 Million	-17,800 Reduced 0.48%	3,709,018 $375 Million
Q2 2020 Aug 13, 2020	BUY	$92.74 - $125.82 $12.7 Million - $17.2 Million	136,595 Added 3.8%	3,726,818 $451 Million
Q1 2020 May 14, 2020	BUY	$79.39 - $115.35 $3.64 Million - $5.28 Million	45,790 Added 1.29%	3,590,223 $340 Million
Q4 2019 Feb 13, 2020	BUY	$78.31 - $95.34 $26 Million - $31.7 Million	332,155 Added 10.34%	3,544,433 $312 Million
Q3 2019 Nov 13, 2019	BUY	$74.85 - $85.99 $12.8 Million - $14.7 Million	171,300 Added 5.63%	3,212,278 $256 Million
Q2 2019 Aug 12, 2019	BUY	$76.06 - $120.81 $60.8 Million - $96.6 Million	799,200 Added 35.65%	3,040,978 $237 Million
Q1 2019 May 14, 2019	BUY	$107.15 - $126.84 $4.82 Million - $5.71 Million	45,000 Added 2.05%	2,241,778 $263 Million
Q4 2018 Feb 13, 2019	BUY	$101.4 - $128.73 $223 Million - $283 Million	2,196,778 New	2,196,778 $239 Million

Others Institutions Holding UTHR

# of Institutions

733

Shares Held

43.6M

Call Options Held

124K

Put Options Held

122K

View Full List

About UNITED THERAPEUTICS Corp

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $14.5B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

More about UTHR

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account